PROFOUND MED CORP PROF 深 滬
等待開盤 09-24 09:30:00 美东时间
5.06
+0.760
+17.67%
華盛通- 最 高5.2495
- 今 開4.35
- 成交量 36.71万股
- 最 低 4.165
- 昨 收 4.30
- 總市值 1.52亿
- 52周最高 9.17
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 3.76
- 委 比 -80.56%
- 總股本 3005.31万
- 歷史最高 28.97
- 量 比 1.05
- 振 幅 25.22%
- 歷史最低 3.10
- 每 手 1
- 風險率 1.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Profound Medical Expands TULSA Program in Texas, Enhancing Prostate Treatment Access
Profound Medical ( ($TSE:PRN) ) just unveiled an announcement. Profound Medical...
09-23 20:44
Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
Profound Medical Corp. has launched a new TULSA program in collaboration with Texas Prostate and Dallas Medical Center to enhance Medicare patient access to advanced prostate treatments. The TULSA Procedure, performed using MRI-guided robotic ultrasound, offers precise ablation of prostate tissue with minimal side effects and no overnight stay. Available under 2025 Medicare coverage, this incision-free procedure addresses prostate cancer and beni...
09-23 12:00
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
Profusa, a digital health company, collaborates with Dr. Koen Deloose, a leading vascular surgeon in Belgium, to advance CLTI treatment using its Lumee Oxygen monitoring system. The partnership aims to improve patient outcomes through innovative technologies and personalized care.
09-04 12:30
Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Profusa, Inc., a digital health company specializing in continuous biochemical monitoring, announced that CEO Ben Hwang will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8–10, 2025, at the Lotte New York Palace Hotel. Dr. Hwang’s presentation will be available on demand starting September 5, 2025, at 7:00am ET for registered investors. The company, based in Berkeley, Calif., develops tissue-integrated senso...
09-02 20:05
Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference
Profound Medical Corp. will participate in the Lake Street Capital Markets “BIG9” Conference on September 11, 2025, in New York City, focusing on investor meetings. The company commercializes TULSA-PRO®, an incision-free prostate treatment using real-time MRI, AI, and ultrasound, and Sonalleve®, for uterine fibroids and bone metastases. Both products are CE marked and approved by regulatory bodies, with TULSA-PRO® also FDA cleared.
08-28 12:00
Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
Profusa, Inc. has announced a collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. Prof. Brodmann will adopt and integrate Profusa's Lumee Oxygen platform technology into her practice, involving approximately 1,500 annual vascular procedures. The collaboration aims to enhance patient monitoring and clinical outcomes while expanding the platform's market reach.
08-27 12:45
Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O’Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
Profusa, a digital health company, has added two key leaders: Peter O’Rourke, former Acting U.S. Secretary of Veterans Affairs, joins the Board of Directors as lead independent director, and Fred Knechtel is appointed Chief Financial Officer. Both will support the company's growth and commercialization efforts.
08-19 12:15
Profound Medical shares are trading lower after the company reported worse-than-expected Q2 financial results.
Profound Medical shares are trading lower after the company reported worse-than...
08-16 00:25
Profound Medical预计2025年营收增长70%-75%
美股周五早盘，Profound Medical（PROF）股价下跌6%，该公司预计2025年营收增长70%-75%，主要得益于其TULSA-AI技术和CA...
08-15 22:31
Profound Medical Q2 EPS $(0.52) Misses $(0.35) Estimate, Sales $2.211M Miss $3.533M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.35) by 47.73 percent. This is a 85.71 percent decrease over losses of $(0.28) per share
08-15 04:09
